Promising Outlook for IDEAYA Biosciences: Buy Rating Backed by Positive Trial Expectations
I'm PortAI, I can summarize articles.
Citi analyst Yigal Nochomovitz maintains a Buy rating on IDEAYA Biosciences (IDYA) due to positive expectations from the Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma. The trial's promising outlook, with anticipated median progression-free survival of 7-8 months, suggests a potential stock price increase. Guggenheim also reiterates a Buy rating with a $50 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments